7.2 Investigational Product (IP) Receipt, Accountability, and Disposition

7.2 Investigational Product (IP) Receipt, Accountability, and Disposition

Investigational Product (IP) management is a critical component of clinical trial execution. Because the safety of subjects and the scientific validity of the trial data depend directly on the quality, identity, and dosage of the IP, regulatory bodies enforce strict controls. In the United States, 21 CFR Part 312 (Investigational New Drug Application) and Part 812 (Investigational Device Exemptions) lay down these requirements, supported by the investigator investigational-product responsibilities in ICH E6(R3) (corresponding to E6(R2) Section 4.6). While the investigator is ultimately responsible for the IP at the clinical site, they may delegate specific tasks to a qualified study pharmacist or coordinator.

1. IP Receipt and Shipping Records

When a shipment of IP arrives at the clinical site, the chain of custody must be documented immediately. The designated receiver must perform a series of checks before accepting the IP into the active inventory:

• Verify Quantities and Details: Cross-reference the physical packages against the shipping manifest. Verify that the lot numbers, kit numbers, strengths, and expiration dates match perfectly.
• Inspect Packaging Integrity: Check for physical damage, leakages, or broken seals on the outer containers and individual kits.
• Check Temperature Indicators: Verify that temperature indicators or digital data loggers (DDLs) shipped with the IP do not show any temperature excursions during transit. If an excursion is indicated, the shipment must be immediately quarantined and the sponsor notified. The IP cannot be dispensed until the sponsor provides written release.
• Documentation: Sign and date the shipping receipt (or electronic portal confirmation) and file all shipping records (packing slips, courier airbills, and bills of lading) in the Investigator Site File (ISF) or pharmacy binder.

2. Storage Conditions and Temperature Management

IP must be stored strictly in accordance with the protocol and the Investigator’s Brochure (IB). Common storage specifications include:

• Controlled Room Temperature: 20°C to 25°C (68°F to 77°F)
• Refrigerated: 2°C to 8°C (36°F to 46°F)
• Frozen: -20°C or -80°C (-4°F or -112°F)

Monitoring and Calibration

Sites must use calibrated digital data loggers (DDLs) to continuously monitor storage temperatures. The DDL must have a current Certificate of Calibration (conforming to National Institute of Standards and Technology - NIST standards). Site staff must record current, minimum, and maximum temperatures daily (or use automated continuous monitoring systems that trigger alerts).

Handling Temperature Excursions

A temperature excursion is any deviation from the protocol-defined storage temperature limits. If an excursion occurs:

1. Quarantine Immediately: Physically isolate the affected IP and label it clearly as "Quarantined - Do Not Dispense."
2. Notify the Sponsor: Contact the sponsor's study monitor and medical monitor immediately. Export and email the DDL temperature log files.
3. Assess Stability: The sponsor will evaluate the stability data of the IP batch to determine if it is still safe and effective for use.
4. Document and Resolve: Receive the sponsor's official written determination (release for use or replace the IP). Document the final decision and file all correspondence in the ISF.

3. IP Dispensing Logs and Patient Compliance

IP must be dispensed only to enrolled subjects in accordance with the protocol. A subject-specific IP Dispensing Log (or Drug Accountability Log) must contain:

• Subject ID.
• Date of dispensing.
• Quantity dispensed (e.g., number of tablets, vial volume).
• Date of return.
• Quantity returned by the subject.
• Expiration date and lot/kit number.
• Initials of the person dispensing the IP.

Subject Compliance Assessment

At each visit, subjects return unused IP (e.g., empty bottles, remaining pills). Site staff count the returned IP and calculate compliance:

Compliance (%) = ((Quantity Dispensed - Quantity Returned) / Expected Consumption) * 100

For example, if a subject was prescribed 2 tablets daily for 14 days (expected consumption = 28 tablets) and returns 6 tablets in the bottle, they consumed 22 tablets. Their compliance is:

Compliance = ((28 - 6) / 28) * 100 = 78.6%

Non-compliance (typically defined as <80% or >120% compliance) must be documented, reported as a protocol deviation, and addressed with subject re-education.

4. IP Accountability and Reconciliation

IP accountability requires a continuous balance sheet that balances perfectly:

Total Received = Total Dispensed to Subjects + Total Returned by Subjects + Total in Inventory + Total Damaged/Lost/Wasted

The monitor (CRA) performs regular IP verification at each monitoring visit. They count physical stock, match it against dispensing logs and source documents, and cross-reference shipping documents.

5. IP Disposition: Return or Destruction

At the end of the trial (or periodically for expired/damaged IP), the IP must be disposed of:

• Return to Sponsor: The site packages the remaining IP, completes a return shipment manifest, and ships it back to the sponsor's designated depot. This is the default method for most trials.
• On-Site Destruction: Some sites (especially large hospitals) have approved standard operating procedures (SOPs) for hazardous waste or drug destruction. On-site destruction can ONLY occur if the sponsor provides written authorization. The site must document the destruction on an IP Destruction Log (including date, method of destruction, quantities, lot numbers, and signatures of the destroyer and a witness). The site provides the sponsor with a Certificate of Destruction.